5 results match your criteria nisvs potential

  • Page 1 of 1

Potentiality of Melittin-Loaded Niosomal Vesicles Against Vancomycin-Intermediate and Staphylococcal Skin Infection.

Int J Nanomedicine 2021 16;16:7639-7661. Epub 2021 Nov 16.

Division of Clinical Microbiology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand.

Background: is an important human pathogen, especially causing skin and soft tissue infections (SSTIs). Over the decades, the infections caused by antibiotic-resistant strains have often become life-threatening. Consequently, exploration and development of competent approaches to combat these serious circumstances are urgently required. Read More

View Article and Full-Text PDF
November 2021

Folic acid-modified nonionic surfactant vesicles for gambogenic acid targeting: Preparation, characterization, and in vitro and in vivo evaluation.

Kaohsiung J Med Sci 2020 May 15;36(5):344-353. Epub 2020 Apr 15.

The College of Pharmacy, Institute of Drug Metabolism, Anhui University of Chinese Medicine, Hefei, China.

The aim of present study was to develop folic acid (FA)-modified nonionic surfactant vesicles (NISVs, niosomes) as carrier systems for targeted delivery of gambogenic acid (GNA). The FA-GNA-NISVs exhibited a mean particle size of 180.77 ± 2. Read More

View Article and Full-Text PDF

PEGylated niosomes-mediated drug delivery systems for Paeonol: preparation, pharmacokinetics studies and synergistic anti-tumor effects with 5-FU.

J Liposome Res 2017 Jun 30;27(2):161-170. Epub 2016 Jun 30.

a Anhui University of Chinese Medicine , Hefei , Anhui , PR China.

This work describes the preparation of a PEGylated niosomes-mediated drug delivery systems for Paeonol, thereby improving the bioavailability and chemical stability of Paeonol, prolonging its cellular uptake and enhancing its synergistic anti-cancer effects with 5-Fu. PEGylated niosomes, which are prepared from biocompatible nonionic surfactant of Spans 60 and cholesterol, and modified with PEG-SA. Pae-PEG-NISVs were evaluated in vitro and in vivo. Read More

View Article and Full-Text PDF

Assessment of the antigen-specific antibody response induced by mucosal administration of a GnRH conjugate entrapped in lipid nanoparticles.

Nanomedicine 2014 Jul 27;10(5):971-9. Epub 2013 Dec 27.

Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde, Glasgow, UK. Electronic address:

Vaccines administered parenterally have been developed against gonadotrophin-releasing hormone (GnRH) for anti-fertility and anti-cancer purposes. The aim of this study was to demonstrate whether mucosal delivery using GnRH immunogens entrapped in lipid nanoparticles (LNP) could induce anti-GnRH antibody titers. Immunogens consisting of KLH (keyhole limpet hemocyanin) conjugated to either GnRH-I or GnRH-III analogues were entrapped in LNP. Read More

View Article and Full-Text PDF

PEGylated non-ionic surfactant vesicles as drug delivery systems for Gambogenic acid.

Drug Deliv 2013 Sep-Oct;20(7):277-84

The Pharmacokinetics Lab, Anhui University of Chinese Medicine , Hefei 230038 , China.

Gambogenic acid (GNA), a popular Chinese traditional medicine, has its limitations of coming into use due to its low aqueous solubility and poor bioavailability. In this study, therefore, the PEGylated non-ionic surfactant vesicles drug delivery systems were prepared from biocompatible non-ionic surfactant of Span60, cholesterol and dicetyl phosphate (DCP) by the improved ethanol injection method, and were modified with a polyethylene glycol monostearate15 (PEG15-SA). PEG15-SA, as a biocompatible, non-toxic and non-immunogenic hydrophilic segment, was grafted onto the surface of colloidal niosomes carries to reduce the uptake by the reticuloendothelial system (RES), prolonging the circulation time and attaining higher entrapment efficiency. Read More

View Article and Full-Text PDF
  • Page 1 of 1